Group 1 - Two stocks in the health care sector are signaling potential warnings for momentum-focused investors as of September 18, 2025 [1] - The Relative Strength Index (RSI) is a key momentum indicator, with values above 70 indicating that a stock may be overbought [2] - Major overbought stocks in the health care sector include 89bio Inc and Anteris Technologies Global Corp [3] Group 2 - 89bio has agreed to be acquired by Roche for $14.50 per share, representing a 79% premium over its closing stock price on September 17, with an RSI value of 82.2 [6] - 89bio's stock has a 52-week high of $11.84 and gained 1.4% to close at $8.08 on Wednesday [6] - Anteris Technologies reported mixed quarterly results, with a stock gain of approximately 48% over the past month and a 52-week high of $8.79, but its shares fell 1.8% to close at $5.61 [6]

Group 1 - Two stocks in the health care sector are showing signs of being overbought, which may concern momentum-focused investors [1][2] - The Relative Strength Index (RSI) is a key momentum indicator, with values above 70 indicating overbought conditions [2] - 89bio Inc has agreed to be acquired by Roche for $14.50 per share, representing a 79% premium over its closing stock price on September 17 [6] - Anteris Technologies reported mixed quarterly results, with a stock price increase of approximately 48% over the past month [6] Group 2 - 89bio's stock has a 52-week high of $11.84 and an RSI value of 82.2, indicating strong momentum [6] - Anteris Technologies has a 52-week high of $8.79 and an RSI value of 75.9, suggesting it is also in an overbought condition [6] - The stock price of 89bio closed at $8.08, while Anteris Technologies closed at $5.61, reflecting recent price movements [6]